This episode features Bernard Vrijens of WestRock Healthcare discussing quantifying the influence of adherence and dose individualization. Read his Commentary which published in the April 2016 issue here.
Listen and subscribe for free on iTunes and Google Play
In this episode, Drs. Scott Marshall from Pfizer, Sandra Visser from Merck, and Amy Cheung from AstraZeneca discuss “Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation”: their White Paper published in the March 2016 issue of PSP. You can get free access the White Paper by clicking here.
Listen and subscribe for free on iTunes and Google Play
This episode features Daniel Hertz of the University of Michigan College of Pharmacy discussing pharmacogenetics and its potential role in screening and treating patients. Read his commentary from the February 2016 issue on Precision Medicine here.
Listen and subscribe for free on iTunes and Google Play
In this episode, Peter Bonate from Astellas, discusses effective communication in systems pharmacology and pharmacometric models. You can read a review of Dr. Bonate’s book Be a Model Communicator and Sell Your Models to Anyone, reviewed by Ellen Leinfuss in the May 2015 issue, by clicking here.
Listen and subscribe for free on iTunes and Google Play
This episode features Sandra Visser and Anne Chain from Merck & Co/MSD, discussing existing practice and modeling approaches and some thoughts with regard to future directions for modeling to assess and predict cardiovascular liabilities of new drugs. You can read Dr. Visser’s Review “Implementation of Quantitative and Systems Pharmacology in Large Pharma” by clicking here.
Listen and subscribe for free on iTunes and Google Play
